Navigation path



Study of Immunogenicity of DNA HIV-1 env, gag and pol Plasmid Vaccines Boosted with MVA in Tanzania: HIV Vaccine Immunogenicity Study
Framework programme:
Project number:
EC contribution:
€ 1 200 000
36 months
Starting date:
December 2002


HIV-l vaccines are urgently needed, especially in developing nations. Also, HIV vaccine study sites are needed in developing nations for more rapid development and deployment of vaccines. DNA plasmid vaccines are promising candidates but their potency needs to be improved. The programme will explore various modes of increasing the immunogenicity of priming with plasmid DNA; intradermal injections, with GM-CSF as adjuvant, intramucosal injections and boosting with a modified vaccinia Ankara vector, MVA. Vaccines produced from subtypes appropriate for Tanzania will be used and a study site will be established in Dar es Salaam. The prerequisites for approval will be addressed on all levels, paving the way for future trials. Immunogenicity studies will continue in Dar es Salaam, with a focus on mucosal immunity and durability of the immune response.


The general objectives of the research are:

1. to optimise the immunisation schedule for DNA vaccine priming and MVA vaccine boosting in the development of HIV-1 preventive vaccines,
2. to develop the expertise and capability to study HIV-1 vaccines in Tanzania.
The specific scientific and technological objectives are:
1. What immunisation schedule is optimal to achieve humoral, CTL and mucosal immunity?
2. Can mucosal immunisation prime for im MVA boosting?
3. Is id immunisation superior to im DNA plasmid immunisation in humans?
4. Can GM-CSF improve id immunisation?
5. What is the durability of immune response after HIV-1 immunisation?

[+] Read More